Fortress Biotech, Inc.
Transaction: 01/02/2026
BUY
Change
+111,209
Price
Not reported
Filing
01/06/2026
Type
BUY
Avenue Therapeutics, Inc.
ATXI • Biotechnology
$0.54
▼ -0.03 (-4.48%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$1.79M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 2.6Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 1:12 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.54
Change-4.48%
Shares Out3.29M
Market Cap$1.79M
Enterprise Value$-147.96K
52W Range0.15 - 0.97
Beta-0.17
P/E-0.65
P/B3.15
P/FCF-1.30
EV/EBITDA0.05
EV/FCF0.11
Price$0.54
Change-4.48%
Shares Out3.29M
Market Cap$1.79M
Enterprise Value$-147.96K
52W Range0.15 - 0.97
Beta-0.17
P/E-0.65
P/B3.15
P/FCF-1.30
EV/EBITDA0.05
EV/FCF0.11
Earnings Yield-154.79%
FCF Yield-77.14%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-2.34%
Profit Margin-2.07%
Debt/Eq0.00
Current Ratio2.60
Quick Ratio2.60
Target$12.00
Target Upside2103.94%
Target Median$12.00
Target Range12.00 - 12.00
Volume10.00
Avg Volume3.24K
EPS Surprise56.04
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
93/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 2.6Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 1 analyst votes · 2026-09-05
100/100
Bullish
Bullish
1
Hold
0
Bearish
0
Price Target
2026-08-12
Low
$12.00
Mean
$12.00
Median
$12.00
High
$12.00
Insider Transactions
Recent executive and insider activity
Fortress Biotech, Inc.
Transaction: 03/31/2025
BUY
Change
+33,724
Price
Not reported
Filing
04/02/2025
Type
BUY
Fortress Biotech, Inc.
Transaction: 12/31/2024
OTHER
Change
0
Price
Not reported
Filing
01/03/2025
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. | BUY | +111,209 | Not reported | 01/02/2026 | 01/06/2026 |
| Fortress Biotech, Inc. | BUY | +33,724 | Not reported | 03/31/2025 | 04/02/2025 |
| Fortress Biotech, Inc. | OTHER | 0 | Not reported | 12/31/2024 | 01/03/2025 |
| Herskowitz Neil | SELL | -23 | $2.00 | 12/02/2024 | 12/03/2024 |
| KRANZLER JAY D | SELL | -61 | $2.24 | 11/05/2024 | 11/07/2024 |
| KRANZLER JAY D | BUY | +497 | $2.50 | 09/30/2024 | 10/01/2024 |
| KRANZLER JAY D | BUY | +3 | $2.40 | 09/27/2024 | 10/01/2024 |
| Charles Faith L. | BUY | +30,000 | $2.46 | 09/23/2024 | 09/25/2024 |
| Jin David | BUY | +65,000 | Not reported | 09/23/2024 | 09/25/2024 |
| KRANZLER JAY D | BUY | +30,000 | $2.46 | 09/23/2024 | 09/25/2024 |
| MacLean Alexandra | BUY | +170,000 | Not reported | 09/23/2024 | 09/25/2024 |
| Oltmans Curtis Gale | BUY | +30,000 | $2.46 | 09/23/2024 | 09/25/2024 |
| Herskowitz Neil | BUY | +30,000 | $2.46 | 09/23/2024 | 09/25/2024 |
| ROSENWALD LINDSAY A MD | BUY | +30,000 | $2.46 | 09/23/2024 | 09/25/2024 |
| Fortress Biotech, Inc. | BUY | +413,507 | Not reported | 04/16/2024 | 04/17/2024 |
| Fortress Biotech, Inc. | BUY | +2,101,496 | Not reported | 01/02/2024 | 01/03/2024 |
| Davidow Robert L | SELL | -18,000 | $0.15 | 12/11/2023 | 12/13/2023 |
| Davidow Robert L | OPTION | 0 | Not reported | 10/31/2023 | 11/28/2023 |
| Fortress Biotech, Inc. | BUY | +418,410 | $0.72 | 09/08/2023 | 09/12/2023 |
| ROSENWALD LINDSAY A MD | BUY | +348,675 | $0.72 | 09/08/2023 | 09/12/2023 |